MSL
TEVA icon

Mackay Shields LLC’s Teva Pharmaceuticals TEVA Stock Holding History

Mackay Shields LLC’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-254,400
Closed -$3.92M – 1440
2018
Q4 		$3.92M Buy
254,400
+126,400
+99% +$2.59M 0.03% 527
2018
Q3 		$2.76M Sell
128,000
-63,800
-33% -$1.48M 0.02% 620
2018
Q2 		$4.66M Buy
+191,800
New +$3.91M 0.03% 495

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Mackay Shields LLC's TEVA Position: Q1 2019 in Review

Mackay Shields LLC sold out of Teva Pharmaceuticals (TEVA) in Q1 2019, closing a stake of 254,400 shares — an estimated $3.92M sold.

Mackay Shields LLC first reported a position in TEVA in Q2 2018 and held it in 3 quarters. The position peaked at $4.66M in Q2 2018. 521 funds tracked by Wall St. Rank hold TEVA as of Q1 2019.

  • Mackay Shields LLC reported no remaining Teva Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Mackay Shields LLC sold 254,400 Teva Pharmaceuticals shares in Q1 2019, an estimated $3.92M.
  • Mackay Shields LLC first reported a position in Teva Pharmaceuticals in Q2 2018 and held it in 3 quarters.
  • Mackay Shields LLC's Teva Pharmaceuticals position peaked at $4.66M in Q2 2018.
  • 521 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2019.

Based on Mackay Shields LLC's 13F filing for Q1 2019, filed 13 May 2019.